Abstract: The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.

Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.

Abstract: An engineered adenovirus penton base protomer, wherein the penton base protomer comprises a first RGD-loop, a second RGD-loop, a variable loop (V loop), an Adenovirus fiber protein binding cleft, and an N-terminal domain; wherein at least one of the first RGD-loop, the second RGD-loop, and the V loop comprises at least one inserted non-adenoviral antigenic polypeptide; and wherein the engineered adenovirus penton base protomer is capable of assembling into virus-like particles (VLPs).

Abstract: Disclosed are chelates resulting from the complexation of bifunctional do2pa derivatives ligands of formula (I), wherein the substituents R1, R1?, R2, R2?, R3, R3?, L1, L1?, L2 and L2? are defined as in the claims, with metallic cations, especially Pb(II) and Bi(III). Also disclosed are bifunctional do2pa derivatives ligands of formula (I), as well as the use of chelates in nuclear medicine and the use of ligands in cations detection or epuration of effluents.

Abstract: The present invention relates to a method for manufacturing a microfluidic device. The microfluidic device includes an input zone adapted to receive a carrier fluid medium and a sample in suspension in the carrier fluid medium, the sample comprising at least one population of cells or microparticles, a confinement zone adapted to confine a selected amount of the sample, and an output zone adapted to discharge the carrier fluid medium and the sample in suspension in the carrier fluid medium.

Abstract: A negative electrode active material for a lithium-ion battery has the following formula (I): Li1-xOHFe1+xS (I). x varies from 0.00 to 0.25, preferably from 0.05 to 0.20.

Abstract: A process for preparing a biocidal, bactericidal and/or bacteriostatic material including the preparation of a polymer precursor solution that has (a) at least one monomer A having a porphyrin group and at least one radical polymerizable function, (b) at least one radical polymerizable monomer B, a photoinitiator, and (c) at least one of the monomers chosen from a monomer C having a quaternary amine and a radical polymerizable function; and/or a monomer D having copper and a radical polymerizable function. Also, the material obtainable by the process and its uses.

Abstract: The treatment of cancer using platinum-based compounds includes certain drawbacks such as biocompatibility, loading efficacy, leakage of drugs during storage and in the bloodstream, more particularly due to the nature of the nanocarriers for platinum delivery. A nanosystem that allows improving platinum-based drug in vivo performance, kinetics and efficacy. In particular, nanoparticles useful as drug delivery system, these nanoparticles being formed from at least: (a) platinum-based drug, (b) poly-L-arginine, and (c) hyaluronic acid. Particularly, these nanoparticles have been tested in terms of entrapment efficiency and also carried out in vitro experiments in 2D cell culture (viability studies on B6KPC3, A549 and HT-29 cells) and 3D cell model (spheroids made of HTC-116) and in vivo experiments (by injecting intravenously to mice the nanoparticles or comparative oxaliplatin solution) to prove their efficiency.

Abstract: The present invention relates to a microfluidic or millifluidic device (1) comprising: —a support (2) made at least partially of a dielectric material, the support (2) comprising a first inlet (21a) adapted to be connected to a first reservoir containing gas, a second inlet (21b) adapted to be connected to a second reservoir containing liquid, an outlet (22) adapted to be connected to a receiver container containing gas and/or liquid, and a main microchannel or millichannel (3) present in the dielectric material allowing the liquid and the gas to flow from the inlets towards the outlet, —one or several ground electrode(s) (4) embedded in said dielectric material and extending along the main microchannel or millichannel (3), and —one or several high-voltage electrode(s) (5) embedded in said dielectric material and extending along the main microchannel or millichannel (3), wherein the high-voltage electrode(s) (5) and the ground electrode(s) (4) are located on opposite sides of the main microchannel or millicha

Abstract: An in-ear stimulation system including a first device configured to be worn at least partially in a first ear canal of a subject and a second device configured to be worn at least partially in a second ear canal of the subject. Each of the first device and the second device includes: at least one in-ear active electrode configured to receive a bio-signal and at least one in-ear reference electrode configured to receive a bio-signal; at least one stimulation device configured for emitting at least one electrical or sensory stimulus; and an electronic system configured to detect at least one bio-signal pattern from the bio-signals measured from the electrodes.

Abstract: Polypeptides having the ability to specifically form connections of glucosyl units in alpha 1,3 on an acceptor having at least one hydroxyl moiety are presented. The polypeptides include i) the pattern I of sequence SEQ ID NO: 1, ii) the pattern II of sequence SEQ ID NO: 2, iii) the pattern III of sequence SEQ ID NO: 3, and iv) the pattern IV of sequence SEQ ID NO: 4, or derivates from one or several of said patterns, wherein the polypeptide furthermore has an aspartic residue (D) at position 5 of the pattern II (SEQ ID NO: 2), a glutamic acid residue (E) at position 6 of the pattern III (SEQ ID NO: 3) an an aspartic acid residue (D) at position 6 of the pattern IV (SEQ ID NO: 4). Methods for producing acceptors connected to glucosyl units in alpha 1,3 using the polypeptides are also provided.

Abstract: A method for detecting movements of a plurality of points (P) of a surface (21), comprising a measuring step during which an incident ultrasonic wave is emitted into the air towards the surface and an ultrasonic wave reflected into the air by the surface (21) is detected. During the measuring step, each measuring point is illuminated by the incident ultrasonic wave at a multiplicity of angles of incidence, and the reflected ultrasonic wave is detected by a network of receiving transducers (3) comprising a plurality of ultrasonic receiving transducers (3a). The movements of the surface are determined at a measuring point by determining a delay and/or a phase shift between two beam-forming signals for said measuring point.

Abstract: A wave shaping device which comprises a tunable impedance surface and a controller connected to the surface in order to control its impedance. The shaping device further comprises a transmission module for receiving a pilot signal used to control the impedance of the surface.

Abstract: The present invention relates to a process for treating aqueous effluents from the primary circuit of a nuclear power plant implementing a separation of boric acid using a reverse osmosis membrane, characterized by the fact that it comprises steps consisting of treating the effluents using a multi-stage assembly composed of reverse osmosis modules comprising a membrane with a high boron rejection rate, arranged in parallel and in series, and recycling of the intermediate products to different points in the assembly.

Abstract: The present invention concerns a reactor for the conversion of carbon dioxide or carbon monoxide into hydrocarbon and/or alcohol comprising a support made from an electrically and thermally conductive material, forming the wall or walls of at least one longitudinal channel that passes through the support and also acting as the cathode of the reactor, at least one wire electrode forming an anode of the reactor, and extending within each longitudinal channel, and being arranged at a distance from the wall or walls of the longitudinal channel, each wire electrode optionally being covered with an electrically insulating layer along the part of the wire electrode extending within the longitudinal channel, a catalyst capable of catalysing a conversion reaction for the conversion of carbon dioxide or carbon monoxide into hydrocarbon and/or alcohol, the catalyst being situated between the wire electrode and the wall or walls of each longitudinal channel.

Abstract: The invention relates to modulating epileptogenicity in a brain of an epileptic patient. The method according to the invention comprises the steps of: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading said models in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in said data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing said at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.

Abstract: A method simulates behavior of a structure by finite element calculation in which a global model represents the structure, a local model represents an area of the structure including geometric details, and an auxiliary model represents the area without the geometric details. The method includes determining by finite element calculation in the global model of a nodal displacement field corresponding to a loading applied to the global model; applying the nodal displacement field to the local and auxiliary models and determining the corresponding forces; calculating a correction when convergence of the solution obtained for the global model is not achieved, and the applying is resumed with a nodal displacement field calculated in the global model after implementing the correction; determining values of internal variables for the different loading increments; and assessing the evolution in the behavior of the structure over time as a function of these values.

Abstract: The invention describes a device (10) for dispensing microbubbles (30) for cell sonoporation, comprising: a tube configured to receive a vial (20) containing a solution (26) of microbubbles (30), at least two catheters (11, 12) arranged inside the tube and opening into the vial (20) when the latter is received by the tube, wherein, when the first catheter (11) is connected to a first air injection source, air can be injected into the vial (20) via the first catheter so as to generate an overpressure therein, the microbubbles (30) contained in the vial (20) entering the second catheter (12) and moving toward its second end (122). The invention also relates to a sonoporation device, a sonoporation process and a computer program product.

Abstract: The present invention relates to a microfluidic device to manipulate, select, treat, or cultivate living bodies, comprising a first chamber, a second chamber and a network of guiding tracks, wherein: said network of guiding tracks comprises at least one first guiding track connecting the first chamber and the second chamber and at least one second guiding track connecting said at least one first guiding track with at least two interconnections; and said at least one second guiding track comprises a curved part; said curved part exhibiting a concavity facing the second chamber or the part of the network connected to the second chamber.

Abstract: The invention relates to 2-octylcyclopropyl-1-carboxylic acid, in particular in the form of one of the isomers thereof in isolated form or in the form of a mixture of at least two of said isomers. The invention further relates to a method for synthesizing 2-octylcyclopropyl-1-carboxylic acid or at least one of the isomers thereof. Finally, the invention relates to the use of 2-octylcyclopropyl-1-carboxylic acid or of one of said isomers in isolated form or of one of the mixtures of at least two of the isomers thereof, as a perfuming agent. The invention further relates to the compositions including 2-octylcyclopropyl-1-carboxylic acid or one of said isomers in isolated form or one of the mixtures of at least two of the isomers thereof, as a perfuming agent.